The disparity was particularly pronounced for non‐early‐stage luminal B breast cancer (adjusted OR 0.6, 0.4–0.9) and HER2‐enriched breast cancer (adjusted OR 0.4, 0.2–1.0; Figure 2A, Table 2), which occurred more frequently in patients without a family history. Here, ERBB2 is linked to breast carcinoma.